Feb. 13 at 2:16 PM
$BIXT has announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with laboratory-confirmed acute viral infection.
https://biotuesdays.com/2026/02/13/bioxytran-reports-positive-phase-2-data-for-prolectin-m/